Cargando…

Antitumor activity of the multikinase inhibitor regorafenib in patient-derived xenograft models of gastric cancer

BACKGROUND: Unresectable gastric cancer is associated with poor outcomes, with few treatment options available after failure of cytotoxic chemotherapy. Clinical trials of targeted therapies have generally shown no survival benefit in gastric cancer, with the exceptions of the antibodies ramucirumab...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huynh, Hung, Ong, Richard, Zopf, Dieter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4625870/ https://www.ncbi.nlm.nih.gov/pubmed/26514182 http://dx.doi.org/10.1186/s13046-015-0243-5

Ejemplares similares

The multikinase inhibitor regorafenib decreases angiogenesis and improves portal hypertension
por: Uschner, Frank Erhard, et al.
Publicado: (2018)

Lupus-Like Glomerulonephritis Associated With Regorafenib, a Multikinase Inhibitor
por: Strasma, Anna, et al.
Publicado: (2021)

Therapeutic Potential of Regorafenib—A Multikinase Inhibitor in Pulmonary Hypertension
por: Veeroju, Swathi, et al.
Publicado: (2021)

Multikinase inhibitor regorafenib inhibits the growth and metastasis of colon cancer with abundant stroma
por: Takigawa, Hidehiko, et al.
Publicado: (2016)

Antitumor effects of regorafenib and sorafenib in preclinical models of hepatocellular carcinoma
por: Kissel, Maria, et al.
Publicado: (2017)

Regorafenib: Antitumor Activity upon Mono and Combination Therapy in Preclinical Pediatric Malignancy Models
por: Daudigeos-Dubus, Estelle, et al.
Publicado: (2015)

Regorafenib (BAY 73-4506): Antitumor and antimetastatic activities in preclinical models of colorectal cancer
por: Schmieder, Roberta, et al.
Publicado: (2014)

Pharmacologic activity and pharmacokinetics of metabolites of regorafenib in preclinical models
por: Zopf, Dieter, et al.
Publicado: (2016)

Synergistic antitumor activity of regorafenib and rosuvastatin in colorectal cancer
por: Yuan, Tao, et al.
Publicado: (2023)

Multikinase Inhibitor Treatment in Thyroid Cancer
por: Ancker, Ole Vincent, et al.
Publicado: (2019)

Rare complications of multikinase inhibitor treatment
por: Pitoia, Fabián, et al.
Publicado: (2018)

Increased intratumoral fluorothymidine uptake levels following multikinase inhibitor sorafenib treatment in a human renal cell carcinoma xenograft model
por: MURAKAMI, MASAHIRO, et al.
Publicado: (2013)

Activity of the multikinase inhibitor dasatinib against ovarian cancer cells
por: Konecny, G E, et al.
Publicado: (2009)

Cabozantinib: an Active Novel Multikinase Inhibitor in Renal Cell Carcinoma
por: Tannir, Nizar M., et al.
Publicado: (2017)

Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors
por: Kumar, R, et al.
Publicado: (2009)

Multikinase inhibitors use in differentiated thyroid carcinoma
por: Jasim, Sina, et al.
Publicado: (2014)

Daily Management of Patients on Multikinase Inhibitors’ Treatment
por: Colombo, Carla, et al.
Publicado: (2022)

Effects of regorafenib on the mononuclear/phagocyte system and how these contribute to the inhibition of colorectal tumors in mice
por: Grünewald, Sylvia, et al.
Publicado: (2023)

Correction: Effects of regorafenib on the mononuclear/phagocyte system and how these contribute to the inhibition of colorectal tumors in mice
por: Grünewald, Sylvia, et al.
Publicado: (2023)

Emerging role of multikinase inhibitors for refractory thyroid cancer
por: Perez, Cesar A, et al.
Publicado: (2012)

Exploring Selectivity of Multikinase Inhibitors across the Human Kinome
por: Miljković, Filip, et al.
Publicado: (2018)

Inhibition of lymphangiogenesis in vitro and in vivo by the multikinase inhibitor nintedanib
por: Lin, Tong, et al.
Publicado: (2017)

Targeting RET-rearranged lung cancers with multikinase inhibitors
por: Sabari, Joshua K., et al.
Publicado: (2017)

Timing of multikinase inhibitor initiation in differentiated thyroid cancer
por: Brose, Marcia S, et al.
Publicado: (2017)

Regorafenib enhances anti-PD1 immunotherapy efficacy in murine colorectal cancers and their combination prevents tumor regrowth
por: Doleschel, Dennis, et al.
Publicado: (2021)

Multikinase inhibitors in the treatment of thyroid cancer: specific role of lenvatinib
por: Stjepanovic, Neda, et al.
Publicado: (2014)

Dermatologic Toxicities in Epidermal Growth Factor Receptor and Multikinase Inhibitors
por: Eaby-Sandy, Beth, et al.
Publicado: (2012)

Autophagy inhibition sensitizes hepatocellular carcinoma to the multikinase inhibitor linifanib
por: Pan, Hongming, et al.
Publicado: (2014)

Clinically relevant drug interactions with multikinase inhibitors: a review
por: Hussaarts, Koen G. A. M., et al.
Publicado: (2019)

E-Cadherin-Deficient Cells Are Sensitive to the Multikinase Inhibitor Dasatinib
por: Bougen-Zhukov, Nicola, et al.
Publicado: (2022)

Use of multikinase inhibitors/lenvatinib in singular thyroid cancer scenarios
por: Zafón, Carles, et al.
Publicado: (2022)

Famitinib exerted powerful antitumor activity in human gastric cancer cells and xenografts
por: Ge, Sai, et al.
Publicado: (2016)

Plocabulin, a novel tubulin inhibitor, has potent antitumor activity in patient-derived xenograft models of gastrointestinal stromal tumors
por: Wang, Yannick, et al.
Publicado: (2020)

Predicting HCC Response to Multikinase Inhibitors With In Vivo Cirrhotic Mouse Model for Personalized Therapy
por: Huang, Daniel Q., et al.
Publicado: (2020)

The novel ATM inhibitor (AZ31) enhances antitumor activity in patient derived xenografts that are resistant to irinotecan monotherapy
por: Greene, Justin, et al.
Publicado: (2017)

Effects of Multikinase inhibitors on pressure overload-induced right ventricular remodelling
por: Kojonazarov, Baktybek, et al.
Publicado: (2013)

SIRT2 Contributes to the Resistance of Melanoma Cells to the Multikinase Inhibitor Dasatinib
por: Karwaciak, Iwona, et al.
Publicado: (2019)

Salvage Therapy With Multikinase Inhibitors and Immunotherapy in Advanced Adrenal Cortical Carcinoma
por: Miller, Kevin C, et al.
Publicado: (2020)

Neoadjuvant Multikinase Inhibitor in Patients With Locally Advanced Unresectable Thyroid Carcinoma
por: Nava, Carla Fernanda, et al.
Publicado: (2019)

The multikinase inhibitor RXDX-105 is effective against neuroblastoma in vitro and in vivo
por: Flynn, Sean M., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_on0qbj9pqodp43jbju9fikmglv